Professional Documents
Culture Documents
Specialty Medical Evidence
Specialty Medical Evidence
OPD Dermatology
Signed By: Cordas,Daniel Michael (Trainee Specialist)
(02/11/2023 11:38)
CONFIDENTIAL
2ND June, 2023.
I had the pleasure of reviewing Rowan with Assoc/Professor Lowe for follow up on Rinvoq 30mg once daily
for atopic dermatitis since 18/8/2022, with dose increased 1/3/2023.
Rowan is compliant with Rinvoq 30mg daily. He was on Keflex QID for several weeks and stopped this four
days ago.
Rowan remains on Valtrex 1g BD for recurrent HSV keratitis for which he sees Ophthalmology at RPAH.
On examination he had generalised xerosis and lichenification. There was ongoing eczema particularly in the
flexural areas. He had crusted vesicles below the right eye which we have swabbed today for bacterial
culture and viral PCR. We have also swabbed an eroded area on the left retroauricular region. He had a
patchy scaly erythematous rash on the anterior chest suspicious for granular parakeratosis. He also had a
curvy linear hypertrophic scar on the right back which we think is secondary to excoriation.
Overall Rowan’s eczema has improved over the last few weeks though remains quite severe to the face with
concern for secondary viral / bacterial infection. Given a possible element of granular parakeratosis also –
we suggest he switches laundry detergents.
2. Left retroauricular
- HSV 1 positive, VZV negative
Page 1 of 2
Page 1 of 3
ROWAN A SCOTT | DOB: 19-Mar-1997 | IHI: 8003 6011 5191 0572
OPD Dermatology
- 3+ Staph argenteus, 3+ S. dysgalactiae
I have discussed the swab results with Prof Lowe. We have asked Rowan to do a basic immunodeficiency
screen including IgG/A/M, IgG subclass, IgE, C3/C4, T and B cell subsets. These remain outstanding.
I have discussed the swab results with the infectious disease registrar, who has suggested flucloxacillin 1g
QID for 7 days, then a prolonged / tapering course as we have previously done with Keflex. He should also
remain on Valtrex 1g BD.
I have liaised with the Ophthalmology registrar who has kindly booked Rowan in for review again, noting he
has missed his recent appointment. Rowan's last attended appointment was on 17/05/23, at which point the
plan was to increase Valtrex 1g BD to TDS for HSV keratitis.
Page 2 of 2
Page 2 of 3
ROWAN A SCOTT | DOB: 19-Mar-1997 | IHI: 8003 6011 5191 0572
Letter
2 Nov 2023
Rowan SCOTT DoB 19 Mar 1997 (26 years*) SEX Male IHI 8003 6011 5191 0572 MRN 1153915
Start of Document
Letter
Attachment
Administrative Details
Primary Recipients
Name Contact Address Organisation
DR JEREMY CHOY Not Provided Not Provided
End of Document
Page 3 of 3